Vogl, NY

 

Breast
54:19

Steven Vogl

Adjuvant Abemaciclib - Are The Data Sufficient? Maybe

  • 265 views
  • January 20, 2022
48:18

Steven Vogl

SABCS 2021 Update: SOFT and TEXT are Important - Ovarian Function Suppression Works!

  • 762 views
  • January 12, 2022
  • 7
25:09

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 on Using the Appearance of a Resistance Mutation in Peripheral Blood as the Sole Evidence to Trigger a Change in Systemic Therapy: PADA-1 Study

FEATURING Steven Vogl
  • 479 views
  • January 4, 2022
  • 5
32:47

SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

FEATURING Steven Vogl
  • 1,357 views
  • January 4, 2022
  • 11
27:32

Steven Vogl

We Need Overall Survival Results From Keynote 355 Now!

  • 819 views
  • January 21, 2021
  • 8
47:44

Steven Vogl

Ovarian Suppression or Cytotoxic Chemotherapy: What Is the Mechanism of Chemo Benefit in RxPonder, and What Should We Do NOW for Premenopausal Women With 1-3+LN, HR+/HER2- BC?

  • 1,167 views
  • January 8, 2021
  • 6
29:48

Steven Vogl

SABCS 2020 RxPONDER Updates on HR+ Node-Positive EBC: Are Postmenopausal Women Able to Avoid Chemotherapy?

  • 2,051 views
  • December 29, 2020
  • 10
18:37

Steven Vogl

POOF: And the Benefit Disappeared! What We Learn From PenelopeB. A Negative Adjuvant CDK4/6 Inhibitor Trial for Resected HR Positive Breast Cancer

  • 1,493 views
  • December 23, 2020
  • 10
25:41

Steven Vogl

Do PD-1 Drugs Really Help Patients With mTNBC to Live Longer and Better?

  • 1,492 views
  • November 23, 2020
  • 17
30:31

Steven Vogl

Discussion on 2020 ESMO Update on CDK4/6i in Adjuvant ER+ Resected BC: Will Recent Major Trials Be Practice Changing?

  • 1,288 views
  • November 13, 2020
  • 11